Items Tagged ‘Idhifa’

August 10th, 2017

FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia


The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the Real Time IDH2 Assay, which is used to detect specific mutations in the IDH2 […]

View full entry

Tags: Acute Myeloid Leukemia, AML, Enasidenib, Idhifa, Leukemia, News